DAVID L. PEARLE, M.D. Professor Director, Coronary Care Unit Pasquerilla Healthcare Center (PHC), 5th Floor Georgetown University Hospital Washington, DC 20007 (202) 444-8833 Office / (202) 444-1839 FAX pearled@gunet.georgetown.edu
Home	Education	Appointments	Licensure	Professional Societies	Committees	Grants	Abstracts	Publications

Research Grants Awarded

1. “Chlordiazepoxide for Ventricular Arrhythmias” American Heart Association, Nation’s Capital Affiliate-1975.
    

2. “Nifedipine, Angina, and Myocardial Infarction Study”, Pfizer laboratories-1979-1982, $72,635, Principal Investigator: David L. Pearle, MD.
    

3. “Nifedipine: To Determine Efficacy in Management of Angina Pectoris”, Pfizer laboratories-1979-1982, Principal Investigator: David L. Pearle, MD.
    

4. “Open, Multi Center Trial of Ibopamine Hydrochloride in Patients with Congestive Heart Failure: Long Term Safety”, Smith, Kline, and French Laboratories- 1984-1987, $176,490, Principal Investigator: David L. Pearle, MD.
    

5. “Double Blind, Placebo-Controlled, Multi Center Trial of Ibopamine in Patients with Congestive Heart Failure: Invasive Evaluation of Hemodynamic Parameters and Exercise Testing”, Smith, Kline, and French Laboratories- 1985-1987, $176,490, Principal Investigator: David L. Pearle, MD.
    

6. “Open Safety Trial of Ibopamine with Captropril and Hydralazine: Acute Hemodynamic Study with Short Term Chronic Dosing”, Smith, Kline, and French Laboratories- 1985-1987, $59,700, Principal Investigator: David L. Pearle, MD.
    

7. “An Optional, Open, Long Term Study of the Effects of Flosequinan 75, 100, or 150 mg q.d. on Safety, Tolerance, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Randomized to the BP1 919 Double Blind Study”, The Boots Company, U.S.A., Inc., $25,000, Principal Investigator: David L. Pearle, MD.
    

8. “An Optional, Open-Label, Long Term Study of the Effects of Flosequinan 100 mg Once a Day (with 150 mg/ 100 mg/ 75 mg/ 50 mg up or down titration) on Safety, Tolerability, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Who Have Participated in BPI-934”, The Boots Company, U.S.A., Inc., $48,000, Principal Investigator: David L. Pearle, MD.
    

9. “Modern Approach to the Treatment of Hypertension Multi-Center Study (MATH)”, Pfizer, Inc., $4,000, Principal Investigator: David L. Pearle, MD.
    

10. “An Open-Label, Compassionate-Use, Long Term Study to Evaluate the of Repeated Daily Oral Doses of Flosequinan in Patients with Congestive Heart Failure”, The Boots Company, U.S.A., Inc., $ N/a, Principal Investigator: David L. Pearle, MD.
     

11. “A Multi-Center, Double Blind, Placebo-Controlled Study of the Effects of Manoplax (Flosequinan) 75 mg Twice Daily or 100 mg Once Daily on Duration of Exercise Treadmill Testing and Disease Symptoms for Up to 12 Weeks in Symptomatic Congestive Heart Failure Patients on Angiotensin Converting Enzyme Inhibitors (ACEIs), The Boots Company, U.S.A., Inc., $180,000, Principal Investigator: David L. Pearle, MD.
     

12. "An Invasive Hemodynamic Study of the Effects, Safety, and Tolerability of 75 mg Twice Daily, 100 mg Once Daily, or 150 mg Once Daily Manoplax (Flosequinan) in New York Heart Association Class III or IV Congestive Heart Failure Patients Uncontrolled by Angiotensin Converting Enzyme Inhibitors (ACEIs) and Diuretics”, The Boots Company, U.S.A., Inc., $420,000, Principal Investigator: David L. Pearle, MD.
     

13. “A Double Blind, Placebo-Controlled, Parallel Group, Invasive Hemodynamic Study with Manoplax (Flosequinan) 75 mg Twice Daily, or 150 mg Once Daily for Two Weeks in New York Heart Association Class III and IV Congestive Heart Failure Patients Symptomatic on Angiotensin Converting Enzyme Inhibitors, BPI 993”, The Boots Company, U.S.A., Inc., $420,700,       Principal Investigator: David L. Pearle, MD.
     

14. “An Open-Label, Long Term Study of the Effects of Manoplax (Flosequinan) 50 mg b.i.d. (with 75 mg b.i.d. upward titration or 25 mg b.i.d. downward titration) on Safety, Tolerability, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Who Have Participated in BPI 993”, The Boots Company, U.S.A., Inc., $89, 800, Principal Investigator: David L. Pearle, MD.
     

15. “U.S. Thrombolysis Registry”, Medical Research International, $ N/a, Principal Investigator: David L. Pearle, MD.
     

16. “Effects of Aminodipine on Exercise Tolerance and Safety in Patients with Chronic, Symptomatic (New York Heart Association Class II-IV) Heart Failure Receiving a Combination of Angiotensin Converting Enzyme Inhibitors, Digoxin, and Diuretics”, Pfizer Laboratories, Funded at $59,368 Current available $11,887 (funds stilled owed), Principal Investigator: David L. Pearle, MD.
     

17. “Long Term Double Blind Evaluation of the Safety of Amlodopine in Patients with Heart Failure (175E)”, Pfizer Laboratories, Funded at $5,00 Current available- $4,832, Principal Investigator: David L. Pearle, MD.
     

18. “A Double Blind Multi Center Comparison of Oral Carvedilol b.i.d. with Placebo in the Treatment of Patients with Congestive Heart Failure, New York Heart Association Class III-IV (221)”, Smith, Kline, and Beecham, Funded at $24,855 (Projected-$72,000) Current available $2,622,       Principal Investigator: David L. Pearle, MD.
     

19. “A Six Month Double Blind Multi Center Comparison of Oral Carvedilol b.i.d. with Placebo  in the Treatment of Patients with Congestive Heart Failure, New York   Heart Association Class III-IV (239)”, Smith, Kline, and Beecham 1992, Funded at $5,145 (Projected-0) Current available $9,606, Principal Investigator: David L. Pearle, MD.
     

20. “A Two Year, Open Label Multi Center, Safety Study of Twice Daily Oral Carvedilol in Patients with New York Heart Association Class I-IV Congestive Heart Failure (Extension)”, Sponsor: Smith Kline and Beecham, Total Grant Amount: $22,760, Amount Funded as of June 1995: $8,535 (Funds due), Status: Active, Principal Investigator: David L. Pearle, MD.
     

21. Achieve Congestive Heart Failure Investigation and Economic Variable Evaluation with Accupril Sponsor: Park Davis. Total Grant Amount: $235/pt. Amount Funded as of June 1995: $1,250 Status: Active. Principal Investigator: David L. Pearle, MD.
     

22. A Multi Center Double Blind Randomized Parallel Design, Pilot Study to Evaluate the Safety and Tolerability of Losartan Administered in Addition to Enalapril in Patients with Heart Failure Treated Previously with ACE Inhibitors. Sponsor: Merck and Co. Total Grant Amount: $45,000. Amount Funded as of June 1995:0. Status: Active. Principal Investigator: David L. Pearle, MD.
     

23. An Open Label Evaluation of Carvedilol in Patients with Chronic Congestive Heart Failure New York Heart Association Class II-IV. Sponsor: Smith Kline and Beecham. Total Grant Amount: $500/pt. Amount Funded as of June 1995: 0. Status: Active. Principal Investigator: David L. Pearle, MD.
     

24. A Six-Month Double Blind, Multi Center Evaluation of Oral Carvedilol b.i.d.  Compared with Placebo in Patients with New York Heart Association Class III-V. Sponsor: Smith Kline and Beecham. Total Grant Amount: $82,850. Amount Funded as of June 1995: $5,145. Status: Closed. Principal Investigator: David L. Pearle, MD. 
     

25. A 12-Month Double Blind, Multi Center Comparison of Oral Carvedilol b.i.d. with Mild Congestive Heart Failure New York Heart Association Class II. Sponsor: Smith Kline and Beecham. Total Grant Amount: $53,795. Amount Funded as of June 1995: $9,606. Status: Closed. Principal Investigator: David L. Pearle, MD.
     

26. BEST Beta-Blocker Evaluation of Survival Trial: Bucindolol. Sponsor: National Heart, Lung, and Blood Institute, Va. Coop. Total Grant Amount: $120,000. Amount Funded as of June 1995: 0. Status: Active. Principal Investigator: David L. Pearle, MD. 
     

27. PRAISE II Prospective Randomized Amlodipine Survival Evaluation. Sponsor: Pfizer, Inc.       Total Grant Amount: to be negotiated. Amount Funded as of June 1995: 0. Status: Active. Principal Investigator: David L. Pearle, MD. 
     

28. VEST Vesnarinone Trial. Sponsor: Otsuka Pharmaceuticals. Total Grant Amount: $78,750. Amount Funded as of June 1995: 0. Status: Active. Principal Investigator: David L. Pearle, MD. 
     

29. The Effect of RO-40 on Exercise Treadmill Test Duration and Al Cause Mortality in Patients with Chronic Congestive Heart Failure New York Heart Association Class II-V Treated for Approximately 3-Years. Sponsor: Hoffman LaRoche. Total Grant Amount: $128,292. Amount Funded as of April 1995: 0. Status: Closed. Principal Investigator: David L. Pearle, MD.